Total Funding
70
72
Total FundingSeries B raised
Growth Score
-6 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
26426
Valitor has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacological properties..
- Gregory Kunst: Chief Executive OfficerPast Role: Aurion Biotechnologies, Founder and Chief Executive Officer
- Steven Lo: Chief Executive OfficerPast Role: Zosano Pharma, President and Chief Executive Officer
About the Company
Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Their technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. They currently
have three development pipelines in the fields of dermatology, ophthalmology, and orthopedics that highlight the capabilities of their novel drug products.
